Alnylam Pharmaceuticals
alnylam.comTotal trials
82
Active
24
Phase 3
15
Total enrollment
24,825
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 16 of 16 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Vutrisiran | — | — | — | — | — | 4 | |
| Sterile Normal Saline | — | — | — | 15 | |||
| Zilebesiran | — | — | — | — | 5 | ||
| Nucresiran | — | — | — | — | — | 2 | |
| ALN-4324 | — | — | — | — | — | 2 | |
| ALN-APP | — | — | — | — | 2 | ||
| ALN-6400 | — | — | — | — | — | 2 | |
| ALN-AGT01 RVR | — | — | — | — | 2 | ||
| ALN-2232 | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| ALN-4915 | — | — | — | — | — | 1 | |
| ALN-BCAT | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| ALN-4285 | — | — | — | — | — | 1 | |
| ALN-5288 | — | — | — | — | — | 1 | |
| ALN-HTT02 | — | — | — | — | — | 1 |
Next readouts
- 2024-05-08
- 2026-12-29
- 2027-04-27
- 2027-05-28
- 2027-06-30
- 2027-07-31
- 2027-08-09
- 2027-08-31
- 2027-09-30
- 2027-12-27
Top conditions
- TTR-mediated Amyloidosis8
- Hypertension6
- Acute Hepatic Porphyria5
- Primary Hyperoxaluria4
- Amyloidosis, Hereditary4
- Type 2 Diabetes Mellitus (T2DM)3
- Respiratory Syncytial Virus Infections3
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy3
Frequently asked questions about Alnylam Pharmaceuticals
- How many clinical trials does Alnylam Pharmaceuticals have on ClinicalTrials.gov?
- Alnylam Pharmaceuticals is listed as the lead sponsor on 82 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Alnylam Pharmaceuticals's trials are in Phase 3?
- 15 of Alnylam Pharmaceuticals's trials are in Phase 3, spread across 16 active drug programs.
- What therapeutic areas does Alnylam Pharmaceuticals focus on?
- Alnylam Pharmaceuticals's most-studied conditions on ClinicalTrials.gov are TTR-mediated Amyloidosis, Hypertension, Acute Hepatic Porphyria, Primary Hyperoxaluria, Amyloidosis, Hereditary.
- When are Alnylam Pharmaceuticals's next clinical trial readouts?
- Alnylam Pharmaceuticals has 10 upcoming primary-completion readouts tracked here; the soonest is “HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy”, expected around 2024-05-08.